title: [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of bortezomib-based chemotherapy for 80 patients with multiple myeloma (MM).
  
  
  METHODS
  A total of 80 cases with a median age of 57 (range: 25-78) years were enrolled in the study. Bortezomib-based regimens included VD (bortezomib and dexamethasone) and PAD (bortezomib, doxorubicin and dexamethasone). 16 of the 80 patients received autologous or allo-hematopoietic stem cell transplantation (HSCT).
  
  
  RESULTS
  The overall response (OR) rate was 80%, including a complete response (CR) of 46.3%. After a median follow-up of 25 months, the 1-year and 2-year overall survival (OS) was 81.4% and 72.9%, and the 2-year progression-free survival (PFS) was 76% and 62.5%, respectively. The 2-year OS and PFS were 100% and 73.9 % in patients with HSCT, while both were 66% (P=0.029) and 58.7% (P=0.447) in patients without HSCT. In univariate analysis, Durie-Salmon group, ISS stage, CR and very good partial response (VGPR), and HSCT were prognostic factors for OS. Gender and extramedullary plasmacytomas were important prognostic factors for PFS. Multivariate analysis by Cox regression revealed that CR and VGPR, Durie-Salmon group A, and HSCT were prognostic factors for better OS; while male and patients without extramedullary plasmacytomas were prognostic factors for longer PFS.
  
  
  CONCLUSIONS
  MM patients could benefit from bortezomib-based chemotherapy with satisfactory efficacy and safety. HSCT could improve the OS for young MM patients.
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Zeyin
authors.initials: Z
authors.lastname: Liang
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Hanyun
authors.initials: H
authors.lastname: Ren
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xinan
authors.initials: X
authors.lastname: Cen
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Lihong
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Jinping
authors.initials: J
authors.lastname: Ou
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Yujun
authors.initials: Y
authors.lastname: Dong
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Yin
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Wensheng
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Zhixiang
authors.initials: Z
authors.lastname: Qiu
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Mangju
authors.initials: M
authors.lastname: Wang
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Weilin
authors.initials: W
authors.lastname: Xu
authors.affiliation: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy*; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib